215 related articles for article (PubMed ID: 28000875)
1. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.
Huang Y; Jiang D; Sui M; Wang X; Fan W
Oncol Rep; 2017 Feb; 37(2):705-712. PubMed ID: 28000875
[TBL] [Abstract][Full Text] [Related]
2. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
[TBL] [Abstract][Full Text] [Related]
4. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
5. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
6. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
7. The trefoil factor 1 (TFF1) protein involved in doxorubicin‑induced apoptosis resistance is upregulated by estrogen in breast cancer cells.
Pelden S; Insawang T; Thuwajit C; Thuwajit P
Oncol Rep; 2013 Sep; 30(3):1518-26. PubMed ID: 23836323
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
10. [Growth inhibition and multidrug resistance-reversing effect of tanshinone I A on human breast cancer cell with estrogen receptor negative].
Jing J; Zheng H; Wang J; Lin P; Zhang J; Xiong ZJ; Wu YY; Ren JJ; Yang HL; Wang XJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):391-5. PubMed ID: 17593814
[TBL] [Abstract][Full Text] [Related]
11. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
13. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
14. Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein.
Zhang Y; Liu X; Zuo T; Liu Y; Zhang JH
Med Oncol; 2012 Jun; 29(2):534-8. PubMed ID: 21562851
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
Yin G; Zeng B; Peng Z; Liu Y; Sun L; Liu C
Oncol Rep; 2018 Mar; 39(3):1215-1226. PubMed ID: 29328488
[TBL] [Abstract][Full Text] [Related]
17. Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells.
Ravizza R; Gariboldi MB; Molteni R; Monti E
Oncol Rep; 2008 Sep; 20(3):625-30. PubMed ID: 18695915
[TBL] [Abstract][Full Text] [Related]
18. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
[TBL] [Abstract][Full Text] [Related]
19. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
[TBL] [Abstract][Full Text] [Related]
20. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
